ReviewArchives of pharmacal research2020
Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.
Review in Archives of pharmacal research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Pooled it
- The Effect of Vitamin C on Pathological Parameters and Survival Duration of Critically Ill Coronavirus Disease 2019 Patients: A Randomized Clinical Trial.Frontiers in immunology · 2021Trial
- Identification of Natural Compounds as Potential COVID-19 Main Protease (Mpro) Inhibitors: A Comprehensive Study andCurrent pharmaceutical design · 2025Review
- COVID-19 and retinal degenerative diseases: Promising link "Kaempferol".Current opinion in pharmacology · 2022Review
- Covid 19-the 21st Century Pandemic: The Novel Coronavirus Outbreak and the Treatment Strategies.Advanced pharmaceutical bulletin · 2022Review
- Knowledge and perceptions of pharmacists' readiness during coronavirus pandemic: the case of United Arab Emirates.Journal of pharmaceutical policy and practice · 2021Article
- Computational studies reveal Fluorine based quinolines to be potent inhibitors for proteins involved in SARS-CoV-2 assembly.Journal of fluorine chemistry · 2021Article
- SARS-CoV-2 and Plasmodium falciparum are probably adopting Analogous strategy to invade erythrocytes.Journal of infection and public health · 2021Article
- Political Partisanship and Antiscience Attitudes in Online Discussions About COVID-19: Twitter Content Analysis.Journal of medical Internet research · 2021Article
- One Year of Coronavirus Disease 2019 (COVID-19) in Brazil: A Political and Social Overview.Annals of global health · 2021Review
- Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.Archives of medical research · 2021Review
- The find of COVID-19 vaccine: Challenges and opportunities.Journal of infection and public health · 2021Review
- Rapid determination of remdesivir (SARS-CoV-2 drug) in human plasma for therapeutic drug monitoring in COVID-19-Patients.Process biochemistry (Barking, London, England) · 2021Article
- Functional and druggability analysis of the SARS-CoV-2 proteome.European journal of pharmacology · 2021Article
- Perspectives on mechanistic implications of ROS inducers for targeting viral infections.European journal of pharmacology · 2021Article
- Brazilian essential oils as source for the discovery of new anti-COVID-19 drug: a review guided by in silico study.Phytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2021Review
- A proposed insight into the anti-viral potential of metallic nanoparticles against novel coronavirus disease-19 (COVID-19).Bulletin of the National Research Centre · 2021Review
- Nanoparticles of ZnO/Berberine complex contract COVID-19 and respiratory co-bacterial infection in addition to elimination of hydroxychloroquine toxicity.Journal of pharmaceutical investigation · 2021Article
- Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment.Frontiers in pharmacology · 2021Review
- The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
A novel coronavirus, later named SARS-CoV-2, was first reported in China in December 2019 and subsequently widely identified in the United States, Japan, South Korea, France, India, and other countries. The disease caused by SARS-CoV-2 infection was called COVID-19. The high fatality and morbidity rates of COVID-19 make it the third largest global epidemic in this century. However, there are currently no approved antiviral drugs for the COVID-19 treatment. Recently, two old antimalarial drugs, hydroxychloroquine and chloroquine, have been found to exert anti-SARS-CoV-2 effects both in vitro and in vivo. Preliminary clinical evidence suggests these drugs may have an effect on the treatment of COVID-19. Herein, we review the pharmacokinetics characteristics and antiviral effects of these drugs, in addition to their side effects and clinical evidence of their use for the COVID-19 treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.